JAK2 and idiopathic pulmonary fibrosis: A single study using PCLS prepared from control subjects and patients with either idiopathic pulmonary fibrosis (IPF) or IPF and PH (IPF + PH) has implicated Janus kinase type 2 (JAK2) as a novel target to oppose contraction of intrapulmonary arteries (Milara et al., 2018).